"Dopamine Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and activate dopamine receptors.
| Descriptor ID |
D018491
|
| MeSH Number(s) |
D27.505.519.625.150.151 D27.505.696.577.150.151
|
| Concept/Terms |
Dopamine Agonists- Dopamine Agonists
- Agonists, Dopamine
- Receptor Agonists, Dopamine
- Dopamine Receptor Agonist
- Agonist, Dopamine Receptor
- Receptor Agonist, Dopamine
- Dopamine Receptor Agonists
- Dopaminergic Agonists
- Agonists, Dopaminergic
- Dopaminergic Agonist
- Agonist, Dopaminergic
- Agonists, Dopamine Receptor
- Dopamine Agonist
- Agonist, Dopamine
|
Below are MeSH descriptors whose meaning is more general than "Dopamine Agonists".
Below are MeSH descriptors whose meaning is more specific than "Dopamine Agonists".
This graph shows the total number of publications written about "Dopamine Agonists" by people in this website by year, and whether "Dopamine Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 3 | 0 | 3 |
| 2000 | 2 | 0 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 2 | 3 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 3 | 4 |
| 2005 | 2 | 1 | 3 |
| 2006 | 0 | 4 | 4 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 2 | 2 |
| 2011 | 1 | 1 | 2 |
| 2014 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dopamine Agonists" by people in Profiles.
-
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. Neurology. 2021 11 16; 97(20):942-957.
-
On demand therapy for Parkinson's disease patients: Opportunities and choices. Postgrad Med. 2021 Sep; 133(7):721-727.
-
The role of dopamine pharmacotherapy and addiction-like behaviors in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2020 08 30; 102:109942.
-
Pharmacological insights into impulsive-compulsive spectrum disorders associated with dopaminergic therapy. Eur J Neurosci. 2019 08; 50(3):2492-2502.
-
Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2016 10 03; 70:77-84.
-
Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease. Mov Disord. 2015 Feb; 30(2):141-9.
-
Variability in quantitative expression of receptors in nonfunctioning pituitary macroadenomas--an opportunity for targeted medical therapy. Endocr Pract. 2014 Jan; 20(1):15-25.
-
Temporal stability of the Unified Dyskinesia Rating Scale. Mov Disord. 2011 Dec; 26(14):2556-9.
-
Repeated cocaine exposure decreases dopamine D2-like receptor modulation of Ca(2+) homeostasis in rat nucleus accumbens neurons. Synapse. 2011 Feb; 65(2):168-80.
-
Treatment of early Parkinson's disease. Part 1. Eur Neurol. 2009; 61(4):193-205.